Home › Research › How common it is
Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study
Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML et al.. JAMA, 2004-06-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Context The Women's Health Initiative Memory Study (WHIMS) previously found increased risk for dementia and no effect on mild cognitive impairment (MCI) in women treated with conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA). Results In the estrogen-alone trial, 47 participants were diagnosed with probable dementia, of whom 28 were assigned to CEE and 19 to placebo (hazard ratio [HR], 1.49; 95% confidence interval [CI], 0.83-2.66). When data were pooled per the original WHIMS protocol, the overall HR for probable dementia was 1.76 (95% CI, 1.19-2.60; P =.005).
What this study adds
Evidence grade: High
This is a trial of 4,532 participants. In the estrogen-alone arm of the Women's Health Initiative Memory Study, 28 women assigned to conjugated equine estrogens and 19 assigned to placebo were diagnosed with probable dementia (hazard ratio 1.49; 95% CI 0.83–2.66). That range includes no difference, so this trial on its own did not show a statistically significant effect.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shumaker, S. A., Legault, C., Kuller, L., Rapp, SR., Thal, L., Lane, D. S., et al. (2004). Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. https://doi.org/10.1001/jama.291.24.2947
Vancouver
Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004. doi:10.1001/jama.291.24.2947. PMID: 15213206.
BibTeX
@article{shumaker2004-15213206,
author = {Shumaker, S. A. and Legault, C. and Kuller, L. and Rapp, SR. and Thal, L. and Lane, D. S. and Fillit, H. and Stefanick, M. L. and others},
title = {{Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study}},
journal = {JAMA},
year = {2004},
doi = {10.1001/jama.291.24.2947},
pmid = {15213206},
url = {https://doi.org/10.1001/jama.291.24.2947}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Context The Women's Health Initiative Memory Study (WHIMS) previously found increased risk for dementia and no effect on mild cognitive impairment (MCI) in women treated with conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA).
- Results In the estrogen-alone trial, 47 participants were diagnosed with probable dementia, of whom 28 were assigned to CEE and 19 to placebo (hazard ratio [HR], 1.49; 95% confidence interval [CI], 0.83-2.66).
- When data were pooled per the original WHIMS protocol, the overall HR for probable dementia was 1.76 (95% CI, 1.19-2.60; P =.005).
Why it matters
In the estrogen-alone arm of the Women's Health Initiative Memory Study, 28 women assigned to conjugated equine estrogens and 19 assigned to placebo were diagnosed with probable dementia (hazard ratio 1.49; 95% CI 0.83–2.66). That range includes no difference, so this trial on its own did not show a statistically significant effect. When the data were pooled "per the original WHIMS protocol", the overall hazard ratio was 1.76 (95% CI 1.19–2.60; P = .005). Neither result suggests this hormone protected against dementia.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Participants4,532
- Evidence strengthHigh
How this study scored 80/100
Published in a top-tier journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (JAMA) |
| Journal's citation record | 4 / 4 | JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2004 — older than 20 years, still counted |
| Sample size | 3 / 4 | 4,532 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 7 / 7 | Cited 1,368 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 57.0 citations a year over 24 year(s) since 2004 |
| Impact for its field and year | 6 / 6 | Cited 68.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 39 other studies in this library |
| Still being cited | 3 / 4 | Cited 120 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Sally Ann Shumaker: h-index 66 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Wake Forest University: institution h-index 835 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 15213206) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 80 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
39 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.